Enhancement of human immunodeficiency virus type 1-specific CD4 and CD8 T cell responses in chronically infected persons after temporary treatment interruption

Journal of Infectious Diseases

Volumn 182, Issue 3, 2000, Pages 766-775

  Papasavvas, Emmanouil ^a   Ortiz, Gabriel M ^e   Gross, Robert ^a,b,c   Sun, Junwei ^a   Moore, E Caroline ^a   Heymann, Jonas J ^e   Moonis, Mona ^a   Sandberg, Johan K ^e   Drohan, Lea Ann ^e   Gallagher, Barbara ^d   Shull, Jane ^d   Nixon, Douglas F ^e   Kostman, Jay R ^c,d   Montaner, Luis J ^a  

^a WISTAR INSTITUTE   (United States)

^b Center for Clinical Epidemiology and Biostatistics   (United States)

^c UNIVERSITY OF PENNSYLVANIA   (United States)

^d Philadelphia Field Initiating Group for HIV 1 Trials   (United States)

^e AARON DIAMOND AIDS RESEARCH CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT; CD4 ANTIGEN; CD8 ANTIGEN; GAG PROTEIN; GAMMA INTERFERON; NEF PROTEIN; VIRUS ENVELOPE PROTEIN;

ADULT; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DOSE TIME EFFECT RELATION; DRUG INTERMITTENT THERAPY; FOLLOW UP; HELPER CELL; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN TISSUE; IMMUNE RESPONSE; MALE; PRIORITY JOURNAL; RISK BENEFIT ANALYSIS; T LYMPHOCYTE ACTIVATION; TREATMENT OUTCOME; VIRUS LOAD;

ADULT; ANTI-HIV AGENTS; CD4-POSITIVE T-LYMPHOCYTES; CD8-POSITIVE T-LYMPHOCYTES; DRUG ADMINISTRATION SCHEDULE; FEMALE; HIV INFECTIONS; HIV-1; HUMANS; IMMUNITY, CELLULAR; INTERFERON TYPE II; LONGITUDINAL STUDIES; MALE; MIDDLE AGED; VIRAL LOAD;

EID: 0033831645     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1086/315748     Document Type: Article

References (54)

1. A controlled trial of two nucleoside analogues plus indinavir in persons with human immunodeficiency virus infection and CD4 cell counts of 200 per cubic millimeter or less
2. Prognosis in HIV-1 infection predicted by the quantity of virus in plasma
3. Status of long-term asymptomatic HIV-1 infection correlates with viral load but not with virus replication properties and cell tropism
4. Serum HIV-1 RNA levels and time to development of AIDS in the Multicenter Hemophilia Cohort Study
5. Report of the NIH panel to define principles of therapy of HIV infection
6. HIV treatment strategies: Planning for the long term
7. Antiretroviral therapy in countries with low health expenditure
8. AIDS researchers target poor adherence
9. + T cells provides a mechanism for lifelong persistence of HIV-1, even in patients on effective combination therapy
10. HIV-1 and HAART: A time to cure, a time to kill
11. Temporal association of cellular immune responses with the initial control of viremia in primary human immunodeficiency virus type 1 syndrome
12. Cellular immune responses to HIV-1 in progressive and non-progressive infections
13. Lymphoproliferative response to HIV type 1 p24 in long-term survivors of HIV type 1 infection is predictive of persistent AIDS-free infection
14. Strong human immunodeficiency virus (HIV)-specific cytotoxic T-lymphocyte activity in Sydney Blood Bank Cohort patients infected with nef-defective HIV type 1
15. Long-term non-progression in HIV infection: Clinicopathological issues
16. Different immunologic profiles characterize HIV infection in highly active antiretroviral therapy-treated and antiretroviral-naive patients with undetectable viraemia
17. HIV type 1 resistance in Kenyan sex workers is not associated with altered cellular susceptibility to HIV type 1 infection or enhanced beta-chemokine production
18. Broadly cross-reactive HIV-specific cytotoxic T-lymphocytes in highly exposed persistently seronegative donors
19. + T cell responses associated with control of viremia
20. Immune control of HIV-1 replication
21. Changes in thymic function with age and during the treatment of HIV infection
22. Improved CD4 lymphocyte outgrowth in response to effective antiretroviral therapy
23. + repertoire during antiviral therapy
24. The effect of commencing combination antiretroviral therapy soon after human immunodeficiency virus type 1 infection on viral replication and antiviral immune responses
25. + T cell homeostasis and function in advanced HIV disease
26. + T-lymphocyte responses after ganciclovir and highly active antiretroviral therapy in individuals infected with HIV-1
27. Immunologic responses associated with 12 weeks of combination antiretroviral therapy consisting of zidovudine, lamivudine, and ritonavir: Results of AIDS Clinical Trials Group protocol 315
28. Long-lasting recovery in CD4 T-cell function and viral-load reduction after highly active antiretroviral therapy in advanced HIV-1 disease
29. Long-term evaluation of T-cell subsets and T-cell function after HAART in advanced stage HIV-1 disease
30. Decrease of cytomegalovirus replication in human immunodeficiency virus-infected patients after treatment with highly active antiretroviral therapy
31. Functional T cell reconstitution and human immunodeficiency virus-1-specific cell-mediated immunity during highly active antiretroviral therapy
32. + T cell demographics and dynamics in lymphatic tissues
33. + T-cell repertoire that are not immediately restored by antiviral or immune-based therapies
34. Development of bivalent rgp 120 vaccines to prevent HIV type infection
35. Advancing AIDSVAX to phase 3. Safety, immunogenicity, and plans for phase 3
36. Quantitation of HIV-1-specific cytotoxic T lymphocytes and plasma load of viral RNA
37. Decay kinetics of human immunodeficiency virus-specific effector cytotoxic T lymphocytes after combination antiretroviral therapy
38. + T cells are detectable in most individuals with active HIV-1 infection, but decline with prolonged viral suppression
39. HIV-1-specific immune responses in subjects who temporarily contain virus replication after discontinuation of highly active antiretroviral therapy
40. Control of HIV despite the discontinuation of antiretroviral therapy
41. Effect of shipment, storage, anticoagulant, and cell separation on lymphocyte proliferation assays for human immunodeficiency virus-infected patients
42. A recombinant vaccinia virus based ELISPOT assay detects high frequencies of Pol-specific CD8 T cells in HIV-1-positive individuals
43. Longitudinal data analysis for discrete and continuous outcomes
44. HIV-1 rebound during interruption of highly active antiretroviral therapy has no deleterious effect on reinitiated treatment
45. An overview of methods for the analysis of longitudinal data
46. Quantifying residual HIV-1 replication in patients receiving combination antiretroviral therapy
47. Persistence of HIV-1 transcription in peripheral-blood mononuclear cells in patients receiving potent anti-retroviral therapy
48. + T cell population with memory rather than naive cells
49. Levels of human immunodeficiency virus type 1-specific cytotoxic T lymphocyte effector and memory responses decline after suppression of viremia with highly active antiretroviral therapy
50. HIV-induced immunopathogenesis
51. + T-cell repopulation kinetics during highly active antiretroviral therapy
52. Biphasic kinetics of peripheral blood T cells after triple combination therapy in HIV-1 infection: A composite of redistribution and proliferation
53. Markers of lymphocyte homing distinguish CD4 T cell subsets that turn over in response to HIV-1 infection in humans